Home › Follicular Lymphoma › New Jersey
Follicular Lymphoma clinical trials in New Jersey
15 studies for Follicular Lymphoma are looking for participants at sites in New Jersey.
Cities in New Jersey
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Hackensack University Medical Center, Hackensack
- Memorial Sloan Kettering Monmouth, Middletown
- and 1 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT07215910A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1311), Hackensack
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07634471A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Hackensack
- Research Site, New Brunswick
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Sep 21, 2026 · NCT06549595SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT04792502A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge
- Hackensack Meridian Health (Data collection only), Hackensack
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT05389293A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833SynKIR-310 for Relapsed/Refractory B-NHL
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 23, 2026 · NCT04998669A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Feb 17, 2026 · NCT07029217Study of SGR-1505 in Mature B-Cell Neoplasms
- Regional Cancer Care Associates, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Brunswick
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.